Discover trends, market shifts, and competitive outlooks for the evenity global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
#How Has The Evenity Market Growth Evolved From 2024 To 2025, And What’s Ahead?#_x000D_
In recent times, the Evenity market has grown by XX (HCAGR). It’s projected to rise from $XX million in 2024 to $XX million in 2025, exhibiting a compound annual growth rate (CAGR) of XX%. The historical growth can be traced back to amplified awareness about osteoporosis and fracture prevention, growing demand for biological drugs, rising elderly population, enhanced diagnostic capabilities, and the high demand for bone health products._x000D_
_x000D_
It is predicted that the size of the evenity market will experience a XX (FCAGR) increase over the coming years, reaching a total market value of $XX million by 2029, with a compound annual growth rate (CAGR) of XX%. The projected market growth during the forecast period can be credited to the heightened acceptance of biologics and advanced injectables, a surge in cases of osteoporosis, the rise in incidences of chronic kidney disease (CKD), increasing cases of rheumatoid arthritis, and a growing occurrence of comorbidities. Key trends to watch during this period include the development of new delivery systems, the merging of digital health tools, the utilization of biosimilars, breakthrough therapies, and advancements in diagnostic technologies._x000D_
_x000D_
#Download a free sample to assess the report’s scope and structure:#_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=20067&type=smp_x000D_
_x000D_
#What Are the Primary Drivers Supporting the Market Growth of the Evenity Market?#_x000D_
The rise in cases of osteoporosis is predicted to fuel the expansion of the evenity market in the future. Osteoporosis, a health condition marked by a reduction in bone density and quality, results in more fragile bones, susceptible to fractures. The escalation in osteoporosis cases results from an aging population experiencing natural bone density decrease and inactive lifestyles that diminish bone strength. Evenity is provided as a monthly shot for a maximum of 12 months to manage osteoporosis by enhancing bone formation, lessening bone resorption, and fortifying bones to evade fractures. For instance, in October 2022, a report by the UK Parliament revealed that osteoporotic fractures presently place direct expenses exceeding $5.8 billion (£4.6 billion) on the NHS, an estimate projected to rise to roughly $7.5 billion (£6 billion) by 2030 due to an aging population. Consequently, the rise in osteoporosis cases underscores the expansion of the evenity market._x000D_
_x000D_
#Which Primary Segments of the Evenity Market Are Driving Growth and Industry Transformations?#_x000D_
The evenity market covered in this report is segmented –_x000D_
_x000D_
1) By Indication: Postmenopausal Osteoporosis, Osteoporosis In Men_x000D_
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies_x000D_
3) By End User: Hospitals And Clinics, Specialty Centers, Homecare Settings, Research And Academic Institutions_x000D_
_x000D_
#Request customized data on this market:#_x000D_
https://www.thebusinessresearchcompany.com/customise?id=20067&type=smp_x000D_
_x000D_
#Which Regions Are Key Players in the Growth of the Evenity Market?#_x000D_
North America was the largest region in the evenity market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the evenity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa._x000D_
_x000D_
_x000D_
_x000D_
_x000D_
#View the full report here:#_x000D_
https://www.thebusinessresearchcompany.com/report/evenity-global-market-report_x000D_
_x000D_
#What Parameters Are Used to Define the Evenity Market?#_x000D_
Evenity (romosozumab) is a biologic medication used to treat osteoporosis in postmenopausal women at high risk of fractures by inhibiting sclerostin, promoting bone growth, and reducing bone loss. Administered through monthly subcutaneous injections, it is typically used for up to 12 months, after which other treatments may be recommended._x000D_
_x000D_
#Purchase the full report and get a swift delivery:#_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20067_x000D_
_x000D_
#About The Business Research Company:#_x000D_
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_
_x000D_
#Get in touch with us:#_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas +1 3156230293_x000D_
Asia +44 2071930708_x000D_
Europe +44 2071930708_x000D_
Email us at info@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
